Search

Your search keyword '"Laille, A"' showing total 632 results

Search Constraints

Start Over You searched for: Author "Laille, A" Remove constraint Author: "Laille, A"
632 results on '"Laille, A"'

Search Results

1. The Parenting Program for the Prevention of Child Abuse.

2. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

4. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

6. P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

7. Malthus y Darwin. Ciencia, educación y formas de vida.

11. Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

13. Understanding public administrators’ and citizens’ preferences for a successful transition to pesticide-free urban green spaces

18. Magic constraints on Gamma-ray emission from Cygnus X-3

19. MAGIC observation of the GRB080430 afterglow

20. Search for an extended VHE gamma-ray emission from Mrk 421 and Mrk 501 with the MAGIC Telescope

21. Gamma-ray excess from a stacked sample of high- and intermediate-frequency peaked blazars observed with the MAGIC telescope

22. MAGIC TeV Gamma-Ray Observations of Markarian 421 during Multiwavelength Campaigns in 2006

23. Simultaneous multi-frequency observation of the unknown redshift blazar PG 1553+113 in March-April 2008

24. Correlated X-ray and Very High Energy emission in the gamma-ray binary LS I +61 303

25. MAGIC Gamma-ray Telescope Observation of the Perseus Cluster of Galaxies: implications for cosmic rays, dark matter, and NGC1275

26. MAGIC Collaboration: Contributions to the 31st International Cosmic Ray Conference (ICRC 2009)

27. The MAGIC Project: Contributions to ICRC 2007

28. Discovery of VHE gamma-ray emission from 1ES1218+30.4

29. Flux upper limit of gamma-ray emission by GRB050713a from MAGIC Telescope observations

30. P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

33. Understanding public administrators' and citizens' preferences for a successful transition to pesticide-free urban green spaces.

35. Supplementary Figure 1 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

36. Supplementary Tables 1-8 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

37. Supplementary Methods Data from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

38. Supplementary Figure 3 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

39. Supplementary Figure 2 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

40. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

41. Malthus y Darwin: Ciencia, educación y formas de vida

42. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)

43. Supplementary Figure 3 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

44. Supplementary Figure 2 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

45. Supplementary Tables 1-8 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

46. Supplementary Figure 1 from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

47. Supplementary Methods Data from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

48. Data from Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

50. Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).

Catalog

Books, media, physical & digital resources